-

09:57:35 AM

UTHR Stock News

UTHR - United Therapeutics Corp

08/03/22 6:00 AM

Nasdaq : UTHR

earnings

United Therapeutics Corporation Reports Second Quarter 2022 Financial Results

United Therapeutics Corporation, a public benefit corporation, today announced its financial results for the quarter ended June 30, 2022. “I’ m extraordinarily pleased with our business performance this past quarter,” said Martine Rothblatt, Ph.D., Chairperson and Chief Executive Officer of United Therapeutics.“ The...

RHEA-AI

very positive

07/27/22 6:00 AM

Nasdaq : UTHR

conferencesearnings

United Therapeutics Corporation to Report Second Quarter 2022 Financial Results Before the Market Opens on Wednesday, August 3, 2022

United Therapeutics Corporation announced today that it will report its second quarter 2022 financial results before the market opens on Wednesday, August 3, 2022. United Therapeutics will host a public webcast Wednesday, August 3, 2022, at 9:00 a.m. Eastern Time. The webcast will be accessible via United...

RHEA-AI

very positive

06/06/22 6:00 AM

Nasdaq, NYSE : UTHR, DDD

United Therapeutics Provides an Update on Its Organ Printing Programs

United Therapeutics Corporation, a public benefit corporation, announced today that in partnership with 3 D Systems Corporation it has produced the world’ s most complex 3 D-printed object– a...

RHEA-AI

neutral

06/03/22 4:30 PM

Nasdaq : UTHR

conferences

United Therapeutics Corporation to Present at the Jefferies Healthcare Conference

United Therapeutics Corporation announced today that James Edgemond, Chief Financial Officer and Treasurer, will provide an overview and update on the company’ s business during a fireside chat session at the Jefferies Healthcare Conference in New York City. The session will take place virtually on Thursday, June...

RHEA-AI

very positive

05/24/22 6:00 AM

Nasdaq : UTHR

fda approval

United Therapeutics Announces FDA Approval of Tyvaso DPI™

United Therapeutics Corporation, a public benefit corporation, announced today that the U.S. Food and Drug Administration has approved Tyvaso DPI™ inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease to improve exercise...

RHEA-AI

very positive

05/04/22 6:00 AM

Nasdaq : UTHR

earnings

United Therapeutics Corporation Reports First Quarter 2022 Financial Results

United Therapeutics Corporation, a public benefit corporation, today announced its financial results for the quarter ended March 31, 2022. “The hard work and dedication of our Unitherians has resulted in double-digit percentage revenue growth year-over-year for Tyvaso, Orenitram, Unituxin, and our total...

RHEA-AI

positive

04/29/22 6:00 AM

Nasdaq : UTHR

clinical trial

United Therapeutics to Feature Clinical Data Across its Commercial and Development Portfolio at the 2022 American Thoracic Society International Conference

United Therapeutics Corporation, a public benefit corporation, today announced that eight posters and three mini-symposia across the company’ s commercial and development portfolio will be presented at the...

RHEA-AI

neutral

04/27/22 6:00 AM

Nasdaq : UTHR

conferencesearnings

United Therapeutics Corporation to Report First Quarter 2022 Financial Results Before the Market Opens on Wednesday, May 4, 2022

United Therapeutics Corporation announced today that it will report its first quarter 2022 financial results before the market opens on Wednesday, May 4, 2022. United Therapeutics will host a public webcast Wednesday, May 4, 2022, at 9:00 a.m. Eastern Time. The webcast will be accessible via United Therapeutics'...

RHEA-AI

very positive

04/06/22 6:00 AM

Nasdaq : UTHR, MNKD

United Therapeutics Announces the Publication of Tyvaso DPI™ BREEZE Clinical and Long-term Data in the Journal Pulmonary Circulation

United Therapeutics Corporation, a public benefit corporation, today announced the publication of additional clinical and long-term safety data from the BREEZE study evaluating Tyvaso DPI™ in patients with pulmonary arterial hypertension in the journal Pulmonary Circulation. “If approved, I believe Tyvaso DPI...

RHEA-AI

neutral

03/08/22 6:00 AM

Nasdaq : UTHR

conferences

United Therapeutics Corporation to Present at the Oppenheimer 32nd Annual Healthcare Conference

United Therapeutics Corporation announced today that James Edgemond, Chief Financial Officer and Treasurer, will provide an overview and update on the company’ s business during a fireside chat session at the Oppenheimer 32 nd Annual Healthcare Conference. The session will take place virtually on Tuesday, March...

RHEA-AI

very positive

1 2 3 4 5 6 7 Next

UTHR Data

IndustryPharmaceutical Preparation Manufacturing
Websitewww.unither.com
CeoMartine Rothblatt
Security nameUnited Therapeutics Corp
Issue typecs
SectorManufacturing
Sic code2834
Employees950
Tags
- Health Technology
- Pharmaceuticals: Other
- Manufacturing
- Pharmaceutical Preparation Manufacturing
Address1040 Spring St
StateMaryland
CitySilver Spring
Zip20910-4018
CountryUnited States
Phone13016089292

About United Therapeutics Corp

United Therapeutics Corporation focuses on the strength of a balanced, value-creating biotechnology model. We are confident in our future thanks to our fundamental attributes, namely our obsession with quality and innovation, the power of our brands, our entrepreneurial culture and our bioinformatics leadership. We also believe that our determination to be responsible citizens - having a positive impact on patients, the environment and society - will sustain our success in the long term. Through our wholly-owned subsidiary, Lung Biotechnology PBC, we are focused on addressing the acute national shortage of transplantable lungs and other organs with a variety of technologies that either delay the need for such organs or expand the supply. Lung Biotechnology is the first public benefit corporation subsidiary of a public biotechnology or pharmaceutical company.